ASH2024注目テーマ④注目演題「#5」
成人慢性ITPへのリルザブルチニブ投与で
迅速で持続的な血小板反応が示される
Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3) (#5)
David J. Kuter(Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, USA)
2025.01.23